ArticleScientific reports2023
Diffusion MRI anomaly detection in glioma patients.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Beyond binary classification: a pilot study of imaging-derived glioma severity modeling using T1-weighted and diffusion MRI radiomics.Magma (New York, N.Y.) · 2026Article
- Evaluation of CNN-based deep learning models for auto-contouring in glioblastoma radiotherapy: a review.Radiation oncology (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffusion-MRI (dMRI) measures molecular diffusion, which allows to characterize microstructural properties of the human brain. Gliomas strongly alter these microstructural properties. Delineation of brain tumors currently mainly relies on conventional MRI-techniques, which are, however, known to underestimate tumor volumes in diffusely infiltrating glioma. We hypothesized that dMRI is well suited for tumor delineation, and developed two different deep-learning approaches. The first diffusion-anomaly detection architecture is a denoising autoencoder, the second consists of a reconstruction and a discrimination network. Each model was exclusively trained on non-annotated dMRI of healthy subjects, and then applied on glioma patients' data. To validate these models, a state-of-the-art supervised tumor segmentation network was modified to generate groundtruth tumor volumes based on structural MRI. Compared to groundtruth segmentations, a dice score of 0.67 ± 0.2 was obtained. Further inspecting mismatches between diffusion-anomalous regions and groundtruth segmentations revealed, that these colocalized with lesions delineated only later on in structural MRI follow-up data, which were not visible at the initial time of recording. Anomaly-detection methods are suitable for tumor delineation in dMRI acquisitions, and may further enhance brain-imaging analysis by detection of occult tumor infiltration in glioma patients, which could improve prognostication of disease evolution and tumor treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.